Related Experiment Videos
Analysis of cellular events using CellCard System in cell-based high-content multiplexed assays
Taosheng Chen1, George Hansen, Oren Beske
1Bristol-Myers Squibb Company, Lead Discovery & Profiling, 5 Research Parkway, Wallingford, CT 06492, USA. taosheng.chen@bms.com
Expert Review of Molecular Diagnostics
|September 10, 2005
Summary
The CellCard System allows simultaneous testing of multiple cell types in one well, improving drug discovery efficiency. This multiplexed assay approach enhances data quality and reduces timelines for compound screening.
Area of Science:
- Biotechnology
- Cell Biology
- Drug Discovery
Background:
- High-content screening (HCS) typically uses single cell types, requiring serial assays for multi-lineage compound analysis.
- Serial assays are time-consuming and limit throughput in drug discovery pipelines.
Purpose of the Study:
- To evaluate the CellCard System for multiplexed, multi-cell type assays.
- To assess the system's utility in determining compound selectivity across diverse cancer cell lines.
Main Methods:
- Utilized the CellCard System to assay ten cancer cell lines simultaneously.
- Applied multiple assays (membrane integrity, cell cycle, apoptosis) to evaluate compound effects.
- Tested a library of compounds with varied mechanisms of action on cellular growth.
Main Results:
- Demonstrated simultaneous determination of cellular responses across ten cell types within a single microtiter well.
- Identified cell type-specific compound effects using multiplexed assays.
- Validated assay performance, data analysis, and results for drug discovery applications.
Conclusions:
- The CellCard System offers a multiplexed approach to enhance assay capacity and data quality.
- This technology can reduce timelines and improve cost-effectiveness in hit identification and lead evaluation.
- The system shows potential for advancing drug discovery through efficient, multi-cell type compound screening.